Institution: Actelion Pharmaceuticals Ltd


Gewerbestrasse 16 ​CH-4123 Allschwil Switzerland

Email: francois.lehembre@actelion.com

Phone: +41615658402

Research interests:

Cancer, melanoma, brain tumors, tumor micro-environment.

Selected publications:

Lehembre F and Regenass U. Metastatic disease: A drug discovery perspective (2012). Seminar in cancer biology. 22: 261-271 Biggs T, Foreman J, Sundstrom L, Regenass U, Lehembre F. Anti-tumor compound testing in glioblastoma organotypic brain cultures (2011). Journal of Biomolecular Screening. 16(8):805-17 Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, Maya M, Zhang F, Wu Q, Lehembre F, Regenass U Fidler IJ. Macitentan (ACT-064992), a Tissue-targeting Endothelin Receptor Antagonist Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer (2011). Neoplasia. 13(2):167-79 Lehembre F, Yilmaz M, Wicki A, Derksen P, Jonkers J, Christofori G. NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. (2008). EMBO J. 27(19):2603-15. Grotegut S, Von Schweinitz D, Christofori G, Lehembre F. Hepatocyte Growth Factor induces cell scattering through MAPK/Egr-1-mediated up-regulation of Snail (2006). EMBO J. 25 (15): 3534-45. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton (2006). Cancer Cell. 9 (4): 261-72. Nacerdine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tanoudji M, Babinet C, Pandolfi PP, Dejean A. The SUMO pathway is essential for nuclear integrity and chromosome Segregation in mice (2005). Developmental Cell. 9 : 1-11. Lehembre F., Muller S, Pandolfi PP, Dejean A. Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. (2001). Oncogene. 20(1): 1-9.

Members List